De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Fresh Tracks Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Fresh Tracks Therapeutics's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 12.8% per year.
Belangrijke informatie
-5.8%
Groei van de winst
100.8%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -12.8% |
| Rendement op eigen vermogen | -57.3% |
| Nettomarge | -71.1% |
| Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14
Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06
Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18Opbrengsten en kosten
Hoe Fresh Tracks Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 23 | 8 | -6 | 11 | 0 |
| 30 Sep 23 | 10 | -9 | 14 | 0 |
| 30 Jun 23 | 3 | -17 | 11 | 0 |
| 31 Mar 23 | 7 | -16 | 13 | 0 |
| 31 Dec 22 | 7 | -21 | 14 | 0 |
| 30 Sep 22 | 5 | -23 | 14 | 0 |
| 30 Jun 22 | 5 | -30 | 14 | 0 |
| 31 Mar 22 | 0 | -40 | 13 | 0 |
| 31 Dec 21 | 0 | -39 | 12 | 0 |
| 30 Sep 21 | 0 | -41 | 12 | 0 |
| 30 Jun 21 | 0 | -32 | 12 | 0 |
| 31 Mar 21 | 1 | -26 | 12 | 0 |
| 31 Dec 20 | 2 | -21 | 12 | 0 |
| 30 Sep 20 | 2 | -24 | 13 | 0 |
| 30 Jun 20 | 4 | -25 | 14 | 0 |
| 31 Mar 20 | 5 | -24 | 12 | 0 |
| 31 Dec 19 | 8 | -14 | 12 | 0 |
| 30 Sep 19 | 10 | -7 | 9 | 0 |
| 30 Jun 19 | 12 | -6 | 6 | 0 |
| 31 Mar 19 | 9 | -7 | 6 | 0 |
| 31 Dec 18 | 11 | -15 | 6 | 0 |
| 31 Dec 17 | 8 | -23 | 6 | 0 |
Kwaliteitswinsten: FRTX is currently unprofitable.
Groeiende winstmarge: FRTX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: FRTX is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Versnelling van de groei: Unable to compare FRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: FRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement op eigen vermogen
Hoge ROE: FRTX has a negative Return on Equity (-57.34%), as it is currently unprofitable.